Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
This study has been completed.
Study NCT00123201   Information provided by Solvay Pharmaceuticals
First Received: July 21, 2005   Last Updated: September 7, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Migraine With Aura
Migraine Without Aura
Additional conditions recognized in this trial
Headache
Migraine Disorders
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Headache Disorders
Headache Disorders, Primary
Nervous System Diseases
Neurologic Manifestations
Pain
Signs and Symptoms
Interventions listed in this trial
Dronabinol MDI
Additional drug interventions recognized in this trial
Tetrahydrocannabinol
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Central Nervous System Agents
Hallucinogens
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Solvay Pharmaceuticals
Nektar Therapeutics


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services